United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company united states of america - 13.3ml bottle - liquid - 10g/100ml - ear nose , oropharynx-oropharynx

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - macrogol 4000 (inn) - powder, for solution - 10 g/sachet - macrogol 4000 (inn) 10 g/sachet

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

esteve pharmaceuticals ltd - lactulose - oral solution - 666.667mg/1ml

Israel - English - Ministry of Health

astrazeneca (israel) ltd - sodium zirconium cyclosilicate - powder for suspension - sodium zirconium cyclosilicate 10 g/sachet - sodium zirconium cyclosilicate - lokelma is indicated for the treatment of hyperkalaemia in adult patients

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

octapharma ltd - normal immunoglobulin human - solution for infusion - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

octapharma ltd - normal immunoglobulin human - solution for infusion - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - normal immunoglobulin human - solution for infusion - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - normal immunoglobulin human - solution for infusion - 50mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

star combo australia pty ltd - natural fish oil, quantity: 500 mg (equivalent: docosahexaenoic acid, qty 60 mg; equivalent: eicosapentaenoic acid, qty 90 mg); euphrasia officinalis, quantity: 25 mg (equivalent: euphrasia officinalis, qty 100 mg); vaccinium myrtillus, quantity: 100 mg (equivalent: vaccinium myrtillus, qty 10 g); tagetes erecta, quantity: 50 mg (equivalent: tagetes erecta, qty 4 g) - capsule, soft - excipient ingredients: iron oxide black; glycerol; lecithin; allura red ac; purified water; d-alpha-tocopherol; gelatin; titanium dioxide; brilliant blue fcf; yellow beeswax; hydrogenated vegetable oil; soya oil - antioxidant/reduce free radicals formed in the body ; maintain/support healthy eye function ; maintain/support eye health ; helps maintain/support eye retina health ; aids/assists eye adaption to variations in light intensity/night vision ; relieve eye soreness ; maintain/support general health and wellbeing

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 10 g - injection, intravenous infusion - excipient ingredients: proline - privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of the following conditions. 1.1 primary humoral immunodeficiency privigen indicated as replacement therapy for primary humoral immunodeficiency (pi). this includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. 1.2 chronic immune thrombocytopenic purpura privigen is indicated for the treatment of patients with chronic immune thrombocytopenic purpura (itp) to raise platelet counts. 1.3 chronic inflammatory demyelinating polyneuropathy privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. limitation of use: privigen maintenance therapy in cidp has not been studied for periods longer than 6 months. after responding during an initial treatment period, not all patients require indefinite maintenance therapy with privigen in order to remain free of cidp symptoms. individualize the duration of any treatment beyond 6 months based upon the patient?s response and demonstrated need for continued therapy.